title: [Clinical Characteristics and Prognosis of 34 Patients with Mantle Cell Lymphoma: A Retrospective Analysis].
abstract: OBJECTIVE
  To study the clinical characteristics and prognostic factors of 34 patients with mantle cell lymphoma (MCL).
  
  
  METHODS
  Clinical records of 34 MCL patients admitted from October 2007 to February 2015 in our hospital were analyzed retrospectively, the influcence of clinical characteristics, therapeutic protocol and biological indicators on overall survival (OS) was investigated.
  
  
  RESULTS
  The median age of the patients at diagnosis was 58.4 years, with a significant male predominance (3.25: 1), 58.8% of patients had bone marrow involvement, 29.4% had alimentary tract involement, and 79.4% were in Ann Arbor stage III-IV. The expected 3 and 5-year overall survival (OS) rates of all the 34 patients were 63.6% and 55.6% respectively. Rituximab in combination with chemotherapy was not significantly superior to chemotherapy alone in terms of OS in this study (68.4 months vs. 51.8 months, P = 0.979). In univariate analysis, absolute monocyte count (AMC) >0.375 × 10(9)/L and increased lactate dehydrogenase (LDH) level at diagnosis were associated with poor OS (P < 0.05).
  
  
  CONCLUSIONS
  Most patients were diagnosed at advanced stage. Rituximab plus chemotherapy can prolong OS time, but no statistically significant difference is observed, which maybe due to the fewer patients in this retrospective study. The high level of AMC and LDH at diagnosis are poor prognostic factors.
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Chen
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Quan-Shun
authors.initials: QS
authors.lastname: Wang
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Na
authors.initials: N
authors.lastname: Lv
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Yong-Hui
authors.initials: YH
authors.lastname: Li
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China. E-mail: jingyu301@126.com.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
authors.affiliation: Medical College of Chinese PLA, Department of Hematology of Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D020522:Lymphoma, Mantle-Cell; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D015996:Survival Rate
chemical_list: D000069283:Rituximab